Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.
Fiche publication
Date publication
mai 2024
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMER Alain
Tous les auteurs :
Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P
Lien Pubmed
Résumé
Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and mutation is now frequently assessed at diagnosis, warranting reexamination of the prognostic parameters.
Référence
J Clin Oncol. 2024 05 24;:JCO2302066